PROVEN IN PATIENTS WITH HFrEF WITH & WITHOUT T2D

FARXIGA can help protect your patients against CV death and hospitalization for heart failure1,2

Mortality due to heart failure is on the rise in the US.3 In fact, weʼve seen a 38% increase in deaths between 2011 and 2017* in which heart failure was the underlying cause.3,† Every patient with HFrEF remains at substantial risk and can deteriorate suddenly.

*2017 US population data derived from the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research data set.3

Underlying cause of death defined as the disease or injury that initiated the series of events leading directly to death.3

Efficacy

IN PATIENTS WITH HFrEF WITH & WITHOUT T2D

Proven to help protect your patients against CV death and hospitalization for heart failure1,2

DAPA-HF: The first outcomes trial with an SGLT2i in patients with HFrEF with and without T2D1,2

DAPA-HF: The First Outcomes Trial in Patients with HFrEF
DAPA-HF: The First Outcomes Trial in Patients with HFrEF
  • The curves separated early and continued to diverge over the study period1
  • The composite end point was driven both by CV death and hospitalization for heart failure2

*Hospitalization for heart failure includes urgent care visits.1

Data represented over a median follow-up of 18.2 months.2

FARXIGA was added on top of heart failure SoC (including an ACEI/ARB/ARNI, BB, MRA, diuretic, etc), unless such use was contraindicated or resulted in unacceptable side effects.2


Safety

FARXIGA has a proven safety profile

Select AEs from DAPA-HF2,4

Safety Profile
Safety Profile

*Major hypoglycemia defined as hypoglycemia requiring the assistance of another person to actively administer carbohydrates, glucagon, or take other corrective action.2

All cases of diabetic ketoacidosis occurred in patients with diabetes at baseline.2

 

Pooled safety data across 12 placebo-controlled clinical studies of glycemic control in patients with T2D1

Adverse reactions reported in ≥2% of patients treated with FARXIGA

Pooled Safety Data Across 12 Placebo Controlled Clinical Studies of Glycemic Control in Patients with T2D
Pooled Safety Data Across 12 Placebo Controlled Clinical Studies of Glycemic Control in Patients with T2D
  • Additional common AEs seen in >2% of patients taking FARXIGA included back pain, dyslipidemia, nasopharyngitis, nausea, and influenza1

n for females: FARXIGA 10 mg=598, placebo=677; n for males: FARXIGA 10 mg=595, placebo=716.1


Study Design

The landmark DAPA-HF trial is the largest SGLT2i study to date for patients with HFrEF1,2,*

Study Design, DAPA-HF
Study Design, DAPA-HF

Baseline medications in DAPA-HF reflected broad use of GDMT 1,2

  • Patients were well-treated on SoC, including BB, diuretics, RAASi therapy (ACEIs, ARBs, ARNI), and MRAs
pills icon

Primary end point1,2:

  • Time to first occurrence of any of the components of the composite of CV death, hospitalization for heart failure, or urgent visit for heart failure

*As of May 2021.


ACEI=angiotensin-converting enzyme inhibitor; AE=adverse event; ARB=angiotensin II receptor blocker; ARNI=angiotensin receptor-neprilysin inhibitor; ARR=absolute risk reduction; BB=beta blocker; CV=cardiovascular; DAPA-HF=Dapagliflozin And Prevention of Adverse outcomes in Heart Failure; eCVD=established cardiovascular disease; eGFR=estimated glomerular filtration rate; HFrEF=heart failure with reduced ejection fraction; HR=hazard ratio; LVEF=left ventricular ejection fraction; MRA=mineralocorticoid receptor antagonist; NNT=number needed to treat; NT-proBNP=N-terminal pro B-type natriuretic peptide; NYHA=New York Heart Association; RAASi=renin-angiotensin aldosterone system inhibitor; RRR=relative risk reduction; SGLT2i=sodium-glucose cotransporter 2 inhibitor; SoC=standard of care; T2D=type 2 diabetes.

IMPORTANT SAFETY INFORMATION FOR FARXIGA